期刊文献+

急性心肌梗死PCI术前应用盐酸替罗非班对患者心肌坏死标记物的影响

急性心肌梗死PCI术前应用盐酸替罗非班对患者心肌坏死标记物的影响
下载PDF
导出
摘要 目的探讨急性心肌梗死PCI术前应用盐酸替罗非班对患者心肌坏死标记物的影响。方法 92例急性心肌梗死行急诊PCI术的病人中48例入院确诊为急性心肌梗死后立即给予盐酸替罗非班后行急诊PCI设为治疗组;44例术前不给盐酸替罗非班仅行急诊PCI术作为对照组。两组术前均嚼服阿司匹林片300mg,硫酸氢氯吡格雷片600mg,两组患者术前、术后24h分别检测磷酸肌酸激酶同工酶(CK-MB)、肌钙蛋白T(cTnT)。结果术后24h两组心肌梗死标记物与术前相比明显升高(P<0.05);术后24h对照组与治疗组相比心肌梗死标记物有明显差异(P<0.05)。结论早期应用盐酸替罗非班可减轻心肌的坏死。 Objective PCI of acute myocardial infarction preoperative application hydrochloride Tirofiban in patients with myocardial necrosis spot on the impact of markers.Methods 92 cases of hospital patients with acute myocardial infarction patients with emergency PCI patients,of which 48 cases admitted to hospital diagnosed as acute myocardial infarction immediately Tirof iban Hydrochloride spot later emergency PCI as the treatment group;44 cases of preoperative do not give hydrochloride for Luo Non-spot only emergent PCI operation as the control group.Preoperatively chewing aspirin tablets 300mg;clopidogrel bisulfate tablets 600mg;two groups of patients with preoperative and postoperative 24h phosphoric acid were used to detect creatine kinase isoenzyme (CK-MB),troponin T (cTnT).Results Group 24hPCI after myocardial infarction markers compared with the preoperative significantly higher (P0.05);after 24h control group and treatment group compared with preoperative myocardial infarction marker Ariake difference (P0.05).Conclusion Early application hydrochloride Tirofiban spot reduce myocardial necrosis.
出处 《当代医学》 2010年第27期1-2,共2页 Contemporary Medicine
关键词 急性心肌梗死 磷酸肌酸激酶同工酶 肌钙蛋白T 急诊PCI Acute myocardial infarction creatine phosphate kinase troponin T emergency PCI
  • 相关文献

参考文献7

  • 1YEH KH,CHEN MC,CHANG HW,et al.Effect of adjunctive tirofiban therapy on angiographic and clinical outcomes in patients with ST-segment elevated acute myocardial infarction undergoing primary stent-ing[J].Jpn Heart J,2004,45(1):31-41.
  • 2SMITH SC J R,FELDMAN TE,HIRSHFELD JW,et al.ACC/AHA/ SCAI 2005 guideline update for percutaneous coronary intervention:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention)[J].Circulation,2006Feb21:113(7):166-286.
  • 3宋玉娥,王琳,李芳,龚培力,王朝晖,党瑜华.盐酸替罗非班对急性冠状动脉综合征的疗效和安全性评价[J].临床心血管病杂志,2006,22(4):220-222. 被引量:71
  • 4WARNHOLTZ A,OSTAD MA,HEITZER T,et sl.Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease[J].Am J Cardiol,2005,95(1):20-23.
  • 5ELLIS SG,TENDERA M,Belder MA,et al.Facilitated PCl in patients with ST--elevation myocardial infarction[J].N Engl J Med,2008,358(21),2205-2217.
  • 6ASSENT-4 PCI Investigatiors.Primay versus tenecteplase-facilitated percutaneous coronary interventions in patients with ST-segment elevation acute myocardial infarction:randomized trial[J].Lancet,2006,367(06):569-578.
  • 7DE LUCA G,SURYAPRANATA H,OTTERMANGER JP,et al.Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction:every minute of delay counts[J].Circulation,2004,109(10):1123-1125.

二级参考文献7

  • 1STONE G W, MOLITERNO D J, BERTRAND M,et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein Ⅱb/Ⅲa in hibitors inpatients undergoing coronary stenting the TARGET trial[J]. Circulation, 2002,105 :2345- 2354.
  • 2CROUCH M A, NAPPI J M, CHEANG K I. Glycoprotein Ⅱb/Ⅲa receptor inbibitors in percutan coronary intervention and acute coronary syndrome [J].Ann Pharmacother, 2003, 37: 860-875.
  • 3FUSTER V, BADIMON L, BADIMON J J, et al.The pathogenesis of coronary artery disease and the acute coronary syndromes [J]. N Engl J Med, 1992,326: 242- 250.
  • 4The Restore Investigators. Effects of platelet Glycoprotein Ⅱb/Ⅲa Blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty[J]. Circulation ,1997, 96: 1445-1453.
  • 5The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.Inhibition of the platelet glycoprotein Ⅱb/Ⅲ a receptor with tirofiban in unstable angina and non-Q-wave rnyocardial infarction[J]. N Engl J Med, 1998, 338:1488-1497.
  • 6BOERSMA E, HARRINGTON R A, MOLITERNO D J, et al. Platelet glycoprotein Ⅱb/Ⅲa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials[J]. Lancet, 2002, 359:189-198.
  • 7TCHENG J E, ELLIS S G, GEORGE B S, et al.Pharmacodynamics of chimetic glycoprotein Ⅱb/Ⅲa integrin antiplatelet antibody Fab TEs in high-risk coronary angioplasty[J]. Circulation, 1994, 90:1757-1764.

共引文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部